Fabry Disease Therapy: State-of-the-Art and Current Challenges.

Article Details

Citation
Copy to clipboard

Azevedo O, Gago MF, Miltenberger-Miltenyi G, Sousa N, Cunha D

Fabry Disease Therapy: State-of-the-Art and Current Challenges.

Int J Mol Sci. 2020 Dec 28;22(1):206. doi: 10.3390/ijms22010206.

PubMed ID
33379210 [ View in PubMed
]
Abstract

Fabry disease (FD) is a lysosomal storage disorder caused by mutations of the GLA gene that lead to a deficiency of the enzymatic activity of alpha-galactosidase A. Available therapies for FD include enzyme replacement therapy (ERT) (agalsidase alfa and agalsidase beta) and the chaperone migalastat. Despite the large body of literature published about ERT over the years, many issues remain unresolved, such as the optimal dose, the best timing to start therapy, and the clinical impact of anti-drug antibodies. Migalastat was recently approved for FD patients with amenable GLA mutations; however, recent studies have raised concerns that "in vitro" amenability may not always reflect "in vivo" amenability, and some findings on real-life studies have contrasted with the results of the pivotal clinical trials. Moreover, both FD specific therapies present limitations, and the attempt to correct the enzymatic deficiency, either by enzyme exogenous administration or enzyme stabilization with a chaperone, has not shown to be able to fully revert FD pathology and clinical manifestations. Therefore, several new therapies are under research, including new forms of ERT, substrate reduction therapy, mRNA therapy, and gene therapy. In this review, we provide an overview of the state-of-the-art on the currently approved and emerging new therapies for adult patients with FD.

DrugBank Data that Cites this Article

Drugs